|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
We have introduced the human estrogen receptor (ER) gene into HeLa cells, a human adenocarcinoma cell line of uterine origin, by infection.
|
1682189 |
1991 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The results of this study show that bcl-2 is relatively highly expressed in proliferative (n = 11) and hyperplastic (n = 18) endometrium, with respective mean staining scores of 3.59 and 3.47 (scale, 0-4), but is significantly (P < 0.001) down-regulated in atypical hyperplasia (n = 11; score, 0.82), and adenocarcinoma (n = 34; score, 0.86). bcl-2 expression did not correlate with stage, grade, estrogen-receptor, or progesterone-receptor expression.
|
8729985 |
1996 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Human adenocarcinoma cells that are either estrogen-receptor positive (such as MCF-7) or estrogen-receptor negative (such as MDA-MB-468) were used as our model system.
|
9848511 |
1998 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Compared to age-matched postmenopausal controls, the ER-alpha/beta ratio was reduced in both grade I adenocarcinoma and MMMT specimens (3.3 and 6.8, respectively), due to a selective loss of ER-alpha.
|
11687977 |
2001 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In addition, intracellular hK4 levels, as detected on Western blot analysis, were induced by 100 nM estrogen treatment of the estrogen receptor positive ovarian carcinoma cell line OVCAR-3, >8-24 h. Our results show that the level of KLK4 expression and expression of KLK4 mRNA variants are associated with progression of ovarian cancer, particularly late stage SER adenocarcinomas.
|
11489814 |
2001 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In Borrmann IV gastric carcinoma ER positive rate was greater than that in other pathologic types, and in poorly differentiated adenocarcinoma and signet ring cell carcinoma the positive rates were greater than those in other histological types of both males and females (P<0.05).
|
12679906 |
2003 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
[Profile of estrogen receptor alpha isoforms in endometrial adenocarcinoma].
|
14674143 |
2003 |
|
Adenocarcinoma
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Comparison of methylation in adenocarcinoma cell lines and tumors versus non-tumor lung tissue showed methylation of ESR1, PGR1 and RASSF1 to be significantly elevated in adenocarcinoma, with RASSF1 being most significant (P=0.0002).
|
15639718 |
2005 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
Comparison of methylation in adenocarcinoma cell lines and tumors versus non-tumor lung tissue showed methylation of ESR1, PGR1 and RASSF1 to be significantly elevated in adenocarcinoma, with RASSF1 being most significant (P=0.0002).
|
15639718 |
2005 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Increasing 14-3-3 sigma expression with declining estrogen receptor alpha and estrogen-responsive finger protein expression defines malignant progression of endometrial carcinoma.
|
16271083 |
2005 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Immunohistochemical evaluation of androgen receptor (AR), estrogen receptor-alpha (ER-alpha), estrogen receptor-beta (ER-beta), and progesterone receptor (PR) was carried out in prostate needle biopsies obtained before and after radiotherapy from 60 patients with adenocarcinoma.
|
15900599 |
2005 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Combining 4 genes (CALCA, DAPK, ESR1 and APC) yielded a sensitivity of 89% (with all adenocarcinomas identified), equal to cytomorphology (89%) and high-risk human papilloma virus (Hr-HPV; 90%).
|
16736496 |
2006 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Estrogen receptor (ER) alpha is expressed at low levels in normal epithelia, and its expression is dramatically up-regulated as transformation progresses during mammary hyperplasia and adenocarcinoma development.
|
17108100 |
2006 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In virgin female mice, pro-lactin overexpression under control of a mammary selective nonhormonally responsive promoter, neu-related lipocalin, results in estrogen receptor alpha (ERalpha)-positive and ERalpha-negative adenocarcinomas.
|
16565509 |
2006 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters.
|
17046193 |
2007 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Coexpression index of estrogen receptor alpha mRNA isoforms in simple, complex hyperplasia without atypia, complex atypical hyperplasia and adenocarcinoma.
|
17561234 |
2007 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Estrogen receptor alpha nuclear expression significantly correlated with adenocarcinoma histology, female gender, and history of never smoking (P = 0.0048 to <0.0001).
|
19706809 |
2009 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Using a script written in R, the diagnostic accuracy of all possible combinations of markers was evaluated and it was shown that a 3 marker panel including vimentin, ER, or PR, and an HPV marker (p16, ProExC, or HPV ISH) is optimal for determining site of origin for usual endometrial and endocervical adenocarcinomas.
|
20534993 |
2010 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Immuno-histochemical examination of the expression of TRPM8 channels in human breast tissues revealed an over-expression of TRPM8 in breast adenocarcinomas, which is correlated with estrogen receptor positive (ER+) status of the tumours.
|
20482834 |
2010 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Human estrogen receptor alpha is highly homologous to estrogen receptor beta and consequently, antibodies used to detect estrogen receptor alpha in breast carcinomas may detect estrogen receptor beta in pulmonary adenocarcinomas.
|
19875957 |
2010 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Such EGFR mutations are frequently found in adenocarcinoma with a strong expression of estrogen receptor (ER) beta, which has been shown to correlate with a favorable prognosis for the patients with EGFR mutations.
|
20615575 |
2011 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, we examined the expression of PGRMC1 and PGRMC2 mRNA by relative quantitative PCR (RelqPCR) and determined whether transcript levels correlate with age, breast cancer staging, estrogen receptor alpha (ERα) status, and other morphometric features routinely used during the pathological examination of breast ductal adenocarcinomas.
|
20655063 |
2011 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
ESR1 gene multiple copies were confirmed in 13/60 (21.6%) breast adenocarcinomas, but high amplification only in 8/13 (62.8%).
|
20458558 |
2011 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
ESR1 gene multiple copies were confirmed in 13/60 (21.6%) breast adenocarcinomas, but high amplification only in 8/13 (62.8%).
|
20458558 |
2011 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Our results indicate that in patients with grade G3 adenocarcinoma, the expression of AT1-R significantly decreased in comparison with G1 patients (p = 0.034), but the level of ERα was the highest in G2 and the lowest in G3.
|
22170435 |
2012 |